drugset / Trial / NCT02260388

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

NCT02260388

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this large comparative effectiveness study led by Richard J. Barohn, MD, of the University of Kansas Medical Center, is to learn about the safety and effectiveness of nortriptyline, duloxetine, pregabalin and mexiletine in treating cryptogenic sensory polyneuropathy (CSPN).

Timeline

Start
2014-10
Primary completion
2017-09
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg
Subject Mexiletine Small molecule 200 mg
Subject Nortriptyline Small molecule 75 mg
Subject Pregabalin Small molecule 100 mg